CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
721 results found-
4 October Final dividend paid 11 October Annual General Meeting 31 December Half Year ends Find out more CSL.com 2024 14 February Half Year results and interim dividend announcement 11 March Shares trade ex-dividend About this report 12 March Record date for interim dividend This Annual Report combines CSL's fi nancial and non-fi nancial performance in one comprehensive account, linking our sustainability 3 April Interim dividend paid and strategic priorities to our business results.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
On 15 February 2017, CSL announced its half year results and new modes of administration
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
On 16 February 2016, CSL announced its half year results indications.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
https://www.csl.com/ -
Release of Half Year From end of relevant half year until the start of the trading day following the release Results to ASX
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/securities-dealing-policy.pdf -
On-market purchases under the plan were made twice yearly, following the announcement of CSL's half and full year results Additional shares may be purchased by NEDs on-market at prevailing share prices in accordance with CSL's Securities Dealing Policy Post-Employment Benefits Superannuation contributions are made in accordance with legislation and are included in the reported base fee, and are not additional to the base fee.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
Topline results from the confirmatory endpoint analysis are expected in the second half of 2023.
https://newsroom.csl.com/2023-05-02-Topline-Results-from-Two-Year-Primary-Efficacy-Endpoint-in-Pivotal-Phase-3-DUPLEX-Study-of-Sparsentan-in-Focal-Segmental-Glomerulosclerosis -
CSL's Code of Responsible Business Practices guides our interactions with stakeholders and sets expectations for responsible business conduct.
https://www.csl.com/sustainability/governance/ethics-and-transparency -
However, less than half of people surveyed said they discuss potential new treatment options or switching treatments with a physician (n=100, 47% and 43% respectively).
https://newsroom.csl.com/2024-01-16-Harris-Poll-Survey-Finds-People-Receiving-Treatment-for-CIDP-Are-Interested-in-Exploring-More-Convenient-Treatment-Options -
11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends Find out more 2021 Key Dates CSL.com 16 February Half year profi t and interim dividend announcement 4 March Shares traded ex-dividend About this report 5 March Record date for interim dividend This is CSL's second annual report where we have combined our 1 April Interim dividend paid financial and non-financial performance in one comprehensive 30 June Full Year ends account, linking our sustainability and strategic priorities to our business results.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf